Business Description
Dawnrays Pharmaceutical (Holdings) Ltd
ISIN : KYG2687M1006
Compare
Compare
Traded in other countries / regions
02348.Hong Kong IPO Date
2003-11-07Description
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.57 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.26 | |||||
| Interest Coverage | 110.76 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.22 | |||||
| Beneish M-Score | -2.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.2 | |||||
| 3-Year EBITDA Growth Rate | 6.1 | |||||
| 3-Year EPS without NRI Growth Rate | 5.1 | |||||
| 3-Year FCF Growth Rate | 16.6 | |||||
| 3-Year Book Growth Rate | 6.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.17 | |||||
| 9-Day RSI | 35.9 | |||||
| 14-Day RSI | 41.98 | |||||
| 6-1 Month Momentum % | 7.76 | |||||
| 12-1 Month Momentum % | 17.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | |||||
| Quick Ratio | 3.04 | |||||
| Cash Ratio | 1.88 | |||||
| Days Inventory | 176.84 | |||||
| Days Sales Outstanding | 57.2 | |||||
| Days Payable | 136.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 6.67 | |||||
| Dividend Payout Ratio | 0.36 | |||||
| 3-Year Dividend Growth Rate | 11.4 | |||||
| Forward Dividend Yield % | 6.67 | |||||
| 5-Year Yield-on-Cost % | 15.65 | |||||
| 3-Year Average Share Buyback Ratio | 0.1 | |||||
| Shareholder Yield % | -1.33 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 57.24 | |||||
| Operating Margin % | 33.91 | |||||
| Net Margin % | 51.92 | |||||
| FCF Margin % | 11.74 | |||||
| ROE % | 18.76 | |||||
| ROA % | 14.93 | |||||
| ROIC % | 14.64 | |||||
| ROC (Joel Greenblatt) % | 47.51 | |||||
| ROCE % | 20.8 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 2.97 | |||||
| PE Ratio without NRI | 5.43 | |||||
| Shiller PE Ratio | 5 | |||||
| Price-to-Owner-Earnings | 6.62 | |||||
| PEG Ratio | 0.85 | |||||
| PS Ratio | 1.54 | |||||
| PB Ratio | 0.51 | |||||
| Price-to-Tangible-Book | 0.62 | |||||
| Price-to-Free-Cash-Flow | 13.19 | |||||
| Price-to-Operating-Cash-Flow | 5.24 | |||||
| EV-to-EBIT | 0.99 | |||||
| EV-to-EBITDA | 0.87 | |||||
| EV-to-Revenue | 0.59 | |||||
| EV-to-FCF | 5.34 | |||||
| Price-to-Projected-FCF | 0.39 | |||||
| Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.8 | |||||
| Price-to-Graham-Number | 0.38 | |||||
| Price-to-Net-Current-Asset-Value | 1.15 | |||||
| Price-to-Net-Cash | 3.64 | |||||
| Earnings Yield (Greenblatt) % | 101.01 | |||||
| FCF Yield % | 7.63 | |||||
| Forward Rate of Return (Yacktman) % | 14.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dawnrays Pharmaceutical (Holdings) Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 1,169.876 | ||
| EPS (TTM) (HK$) | 0.404 | ||
| Beta | 0.33 | ||
| Volatility % | 15.57 | ||
| 14-Day RSI | 41.98 | ||
| 14-Day ATR (HK$) | 0.031018 | ||
| 20-Day SMA (HK$) | 1.239 | ||
| 12-1 Month Momentum % | 17.92 | ||
| 52-Week Range (HK$) | 1 - 1.4 | ||
| Shares Outstanding (Mil) | 1,500.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dawnrays Pharmaceutical (Holdings) Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dawnrays Pharmaceutical (Holdings) Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dawnrays Pharmaceutical (Holdings) Ltd Frequently Asked Questions
What is Dawnrays Pharmaceutical (Holdings) Ltd(HKSE:02348)'s stock price today?
The current price of HKSE:02348 is HK$1.20. The 52 week high of HKSE:02348 is HK$1.40 and 52 week low is HK$1.00.
When is next earnings date of Dawnrays Pharmaceutical (Holdings) Ltd(HKSE:02348)?
The next earnings date of Dawnrays Pharmaceutical (Holdings) Ltd(HKSE:02348) is .
Does Dawnrays Pharmaceutical (Holdings) Ltd(HKSE:02348) pay dividends? If so, how much?
The Dividend Yield %  of Dawnrays Pharmaceutical (Holdings) Ltd(HKSE:02348) is 6.67% (As of Today), Highest Dividend Payout Ratio of Dawnrays Pharmaceutical (Holdings) Ltd(HKSE:02348) was 0.38. The lowest was 0.08. And the median was 0.31. The  Forward Dividend Yield % of Dawnrays Pharmaceutical (Holdings) Ltd(HKSE:02348) is 6.67%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers